HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Investigation of postoperative adjuvant chemotherapy in patients with transitional cell carcinoma of the upper urothelium. Nara Urooncology Research Group (NUORG)].

Abstract
During the 5 years from January, 1985 to December, 1989, 88 patients with transitional cell carcinoma of the renal pelvis and/or ureter were operated curatively in the Department of Urology, Nara Medical University and the affiliated hospitals. There were 66 males and 22 females (3:1) and the mean age was 66.0 years old ranging from 34 to 82. Staging of the renal pelvic and ureteral cancer of each patient was determined by General Rule for Clinical and Pathological Studies on Renal Pelvic and Ureteral Cancer established jointly by Japanese Urological Association and The Japanese Society of Pathology in 1990. The over-all survival rates at 1 and 3 years were 91.2% and 74.0%, respectively. The 3 year survival rates of TS and TE were 80.5% and 41.7%. As for grading, the 3-year survival rates were 75.0% for G1, 70.1% for G2, and 75.2% for G3, respectively. The stage of the tumors affected the prognosis. Of 88 patients 26 (Group 1) received cisplatin based combination chemotherapy as a postoperative adjuvant therapy, and the remaining 62 (Group 2) received no such cytotoxic adjuvant chemotherapy. The 3-year survival rates were 63.3% in Group 1 and 78.9% in Group 2, however mean age of Group 1 was significantly younger than that of Group 2. In spite of the age matched trial, there were no significant differences in survival rates between both groups. Adverse effects of cisplatin based combination chemotherapy included gastrointestinal symptom, fatigue, alopecia and leukopenia, however no serious toxicity was seen. These results suggest that prospective randomized trial would be clarified the efficacy of postoperative adjuvant chemotherapy for patients with renal pelvic and/or ureteral cancer.
AuthorsH Uemura, S Ozono, Y Hayashi, Y Hirao, E Okajima, H Aoyoma, K Sasaki, S Ohara, M Hashimoto, M Yoshikawa
JournalNihon Hinyokika Gakkai zasshi. The japanese journal of urology (Nihon Hinyokika Gakkai Zasshi) Vol. 82 Issue 8 Pg. 1273-80 (Aug 1991) ISSN: 0021-5287 [Print] Japan
PMID1921019 (Publication Type: Clinical Trial, English Abstract, Journal Article, Multicenter Study)
Chemical References
  • Vinblastine
  • Doxorubicin
  • Cyclophosphamide
  • Cisplatin
  • Methotrexate
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Carcinoma, Transitional Cell (drug therapy, mortality)
  • Chemotherapy, Adjuvant
  • Cisplatin (administration & dosage)
  • Cyclophosphamide (administration & dosage)
  • Doxorubicin (administration & dosage)
  • Female
  • Humans
  • Male
  • Methotrexate (administration & dosage)
  • Middle Aged
  • Survival Rate
  • Urologic Neoplasms (drug therapy, mortality)
  • Vinblastine (administration & dosage)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: